Precisely Engineered Cells. Powerful Therapeutics.

At Ernexa Therapeutics, we believe the body holds powerful tools for healing. Our job is to help reactivate them. Through innovative cell therapies, we are addressing the immune dysregulation that underlies cancer and autoimmune disease to help restore what illness seeks to erode: strength, resilience, and hope.

Our core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution without needing patient-specific cell harvesting.

ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-102 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.

Our Mission & Vision

At Ernexa Therapeutics, our mission is to transform the treatment of cancer and autoimmune disease by developing scalable, affordable, off-the-shelf cell therapies that restore hope.

We envision a future where cell therapies powered by synthetic iMSCs can offer new options for patients with limited treatment paths.

Leadership Team

Ernexa Therapeutics’ leadership team brings together deep expertise in cell therapy, immunology, and biotech innovation. We come with a shared belief in the power of stem cell science to rewrite what’s possible for patients. We are scientists, builders, business leaders, and problem-solvers committed to advancing therapies that break through immune defenses and deliver lasting hope.

Leadership